Bisan has been advised that the ASX has determined that the Company does not comply with Listing Rule 12.1 and the assets and operations of the Company are not sufficient to warrant the continued quotation of the Company’s securities to trading on ASX.
The ASX has stated that it will afford the Company until 1 November 2017 to demonstrate to ASX that it is compliant with listing rule 12.1. If the Company does not demonstrate compliance with this rule to ASX’s satisfaction by 1 November 2017, ASX may suspend the Company’s securities from official quotation
Has BSN complied with listing rule 12.1 with a $50,000 investment?
BSN Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
